(Total Views: 555)
Posted On: 07/14/2021 1:50:15 PM
Post# of 148878
Pitt managed to post the email on YMB:
Quote.
"I've tried posting actual message again.
Dr. Woodcock, we've exchanged emails numerous times. I've thanked and applauded you and I've spoken harshly toward you as well. I apologized for that and you accepted that.
I once again applaud you requesting an investigation into Biogen's recent approval.
So my request is would you please have an investigation into the Leronlimab trial? It barely missed significance to critical patients P value even after the trial was based on 28 days with only 2 shots administered on day 0 and day 7 of the trial. The drug has a 10 day half life. That's why it showed a 82% efficacy at day 14 and dropped to 23% by day 28 which is still amazing considering the half life and no shot past day 7. What I don't understand was why the DSMC never suggested a trial modification in dosage or numbers of patients? Also the FDA never comments on trials under review then sent out a letter stating Leronlimab had no effect on covid and did not meet secondary or primary end points. I've always been honest with you. I do have an retirement investment in this stock and did due diligence over a year ago. But to see this drug withheld that can help people is upsetting. I just don't see how barely missing a P Value means no effect on covid. Hopefully long haulers , cancer and HIV trials and BLA will go well.
Thanks and please consider my request.
Thank you for writing. I will take your request into account. Janet Woodcock!"
endquote
WUM
Quote.
"I've tried posting actual message again.
Dr. Woodcock, we've exchanged emails numerous times. I've thanked and applauded you and I've spoken harshly toward you as well. I apologized for that and you accepted that.
I once again applaud you requesting an investigation into Biogen's recent approval.
So my request is would you please have an investigation into the Leronlimab trial? It barely missed significance to critical patients P value even after the trial was based on 28 days with only 2 shots administered on day 0 and day 7 of the trial. The drug has a 10 day half life. That's why it showed a 82% efficacy at day 14 and dropped to 23% by day 28 which is still amazing considering the half life and no shot past day 7. What I don't understand was why the DSMC never suggested a trial modification in dosage or numbers of patients? Also the FDA never comments on trials under review then sent out a letter stating Leronlimab had no effect on covid and did not meet secondary or primary end points. I've always been honest with you. I do have an retirement investment in this stock and did due diligence over a year ago. But to see this drug withheld that can help people is upsetting. I just don't see how barely missing a P Value means no effect on covid. Hopefully long haulers , cancer and HIV trials and BLA will go well.
Thanks and please consider my request.
Thank you for writing. I will take your request into account. Janet Woodcock!"
endquote
WUM
(15)
(0)Scroll down for more posts ▼
